XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.87

+1.3%

Feb 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: chirodoc who wrote (4790)	11/20/1997 1:46:00 PM
From: Pseudo Biologist	Read Replies (1) of 17367

chirodoc, thanks for the comments. The conditions BPI treats are complicated and "multifactorial," so its development is not easy, and it will take exceptional skill to pull this through. Listening to Giroir was a good step, as he seemed to have made the point (which is well beyond my knowledge to agree or disagree with) that meningoccemia was a disease "made to order" for BPI (or the other way around). Management will not "give away" BPI, but if clinical trials (and perceptions thereof) are not managed wisely, they may have some tough choices ahead of them. chirodoc, I will post something about Arris/Sequana, etc in the Arris thread later today. PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next